Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,144
archived clinical trials in
Ocular

Increasing Patching for Amblyopia in Children 3 to < 8 Years Old
Increasing Patching for Amblyopia in Children 3 to < 8 Years Old
Status: Enrolling
Updated:  7/12/2016
Duke University Eye Center
mi
from
Durham, NC
Increasing Patching for Amblyopia in Children 3 to < 8 Years Old
Increasing Patching for Amblyopia in Children 3 to < 8 Years Old
Status: Enrolling
Updated: 7/12/2016
Duke University Eye Center
mi
from
Durham, NC
Click here to add this to my saved trials
Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions for the Treatment of Keratoconjunctivitis Sicca in Patients With Chronic Ocular Graft Versus Host Disease
Status: Enrolling
Updated:  7/12/2016
U. Miami - Bascom Palmer Eye Institute
mi
from
Plantation, FL
Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions for the Treatment of Keratoconjunctivitis Sicca in Patients With Chronic Ocular Graft Versus Host Disease
Status: Enrolling
Updated: 7/12/2016
U. Miami - Bascom Palmer Eye Institute
mi
from
Plantation, FL
Click here to add this to my saved trials
Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions for the Treatment of Keratoconjunctivitis Sicca in Patients With Chronic Ocular Graft Versus Host Disease
Status: Enrolling
Updated:  7/12/2016
Massachusetts Eye & Ear Infirmary
mi
from
Boston, MA
Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions for the Treatment of Keratoconjunctivitis Sicca in Patients With Chronic Ocular Graft Versus Host Disease
Status: Enrolling
Updated: 7/12/2016
Massachusetts Eye & Ear Infirmary
mi
from
Boston, MA
Click here to add this to my saved trials
Femtosecond Laser Assisted Cataract Surgery in Intumescent Cataracts
Femtosecond Laser Assisted Cataract Surgery in Intumescent Cataracts
Status: Enrolling
Updated:  7/12/2016
Contact Alcon Call Center for Trial Locations
mi
from
Fort Worth, TX
Femtosecond Laser Assisted Cataract Surgery in Intumescent Cataracts
Femtosecond Laser Assisted Cataract Surgery in Intumescent Cataracts
Status: Enrolling
Updated: 7/12/2016
Contact Alcon Call Center for Trial Locations
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye
Status: Enrolling
Updated:  7/13/2016
Sall Research Center
mi
from
Artesia, CA
Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye
Status: Enrolling
Updated: 7/13/2016
Sall Research Center
mi
from
Artesia, CA
Click here to add this to my saved trials
Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye
Status: Enrolling
Updated:  7/13/2016
Lugene Eye Institute
mi
from
Glendale, CA
Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye
Status: Enrolling
Updated: 7/13/2016
Lugene Eye Institute
mi
from
Glendale, CA
Click here to add this to my saved trials
Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye
Status: Enrolling
Updated:  7/13/2016
Montebello Medical Center, Inc.
mi
from
Montebello, CA
Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye
Status: Enrolling
Updated: 7/13/2016
Montebello Medical Center, Inc.
mi
from
Montebello, CA
Click here to add this to my saved trials
The Effects of Cyclosporin A in a Low Humidity Environment, on the Ocular Surface
The Effects of Cyclosporin A Emulsion, (Restasis), on the Ocular Surface in Response to Low Humidity Environment in Patients With Dry Eye
Status: Enrolling
Updated:  7/19/2016
Alkek Eye Center, Dept of Ophthalmology, Baylor College of Medicine
mi
from
Houston, TX
The Effects of Cyclosporin A in a Low Humidity Environment, on the Ocular Surface
The Effects of Cyclosporin A Emulsion, (Restasis), on the Ocular Surface in Response to Low Humidity Environment in Patients With Dry Eye
Status: Enrolling
Updated: 7/19/2016
Alkek Eye Center, Dept of Ophthalmology, Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Anatomic Outcomes Following Ozurdex Injections
Anatomic Outcomes Following Ozurdex Injection
Status: Enrolling
Updated:  7/26/2016
Barnes Retina Institute
mi
from
St. Louis, MO
Anatomic Outcomes Following Ozurdex Injections
Anatomic Outcomes Following Ozurdex Injection
Status: Enrolling
Updated: 7/26/2016
Barnes Retina Institute
mi
from
St. Louis, MO
Click here to add this to my saved trials
Dexamethasone Intravitreal Implant After Vitrectomy For Epiretinal Membrane
Dexamethasone Intravitreal Implant After Vitrectomy for Idiopathic Epiretinal Membrane
Status: Enrolling
Updated:  7/26/2016
St. Luke's Hospital
mi
from
Chesterfield, MO
Dexamethasone Intravitreal Implant After Vitrectomy For Epiretinal Membrane
Dexamethasone Intravitreal Implant After Vitrectomy for Idiopathic Epiretinal Membrane
Status: Enrolling
Updated: 7/26/2016
St. Luke's Hospital
mi
from
Chesterfield, MO
Click here to add this to my saved trials
Dexamethasone Intravitreal Implant After Vitrectomy For Epiretinal Membrane
Dexamethasone Intravitreal Implant After Vitrectomy for Idiopathic Epiretinal Membrane
Status: Enrolling
Updated:  7/26/2016
St. Louis Eye Surgery and Laser Center
mi
from
St. Louis, MO
Dexamethasone Intravitreal Implant After Vitrectomy For Epiretinal Membrane
Dexamethasone Intravitreal Implant After Vitrectomy for Idiopathic Epiretinal Membrane
Status: Enrolling
Updated: 7/26/2016
St. Louis Eye Surgery and Laser Center
mi
from
St. Louis, MO
Click here to add this to my saved trials
Dexamethasone Intravitreal Implant After Vitrectomy For Epiretinal Membrane
Dexamethasone Intravitreal Implant After Vitrectomy for Idiopathic Epiretinal Membrane
Status: Enrolling
Updated:  7/26/2016
The Retina Institute
mi
from
St. Louis, MO
Dexamethasone Intravitreal Implant After Vitrectomy For Epiretinal Membrane
Dexamethasone Intravitreal Implant After Vitrectomy for Idiopathic Epiretinal Membrane
Status: Enrolling
Updated: 7/26/2016
The Retina Institute
mi
from
St. Louis, MO
Click here to add this to my saved trials
How Has Glaucoma Affected Your Quality of Life?
A Prospective, Longitudinal, Observational Cohort Study Examining How Glaucoma Affects Quality of Life and Visual Function Over a 4-Year Period
Status: Enrolling
Updated:  7/26/2016
Wills Eye Institute
mi
from
Philadelphia, PA
How Has Glaucoma Affected Your Quality of Life?
A Prospective, Longitudinal, Observational Cohort Study Examining How Glaucoma Affects Quality of Life and Visual Function Over a 4-Year Period
Status: Enrolling
Updated: 7/26/2016
Wills Eye Institute
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy/Safety of Human Plasminogen Eye Drop in Ligneous Conjunctivitis Patients
A Historically Controlled Phase II/III Study to Evaluate Efficacy and Safety of Kedrion Human Plasminogen Eye Drop Preparation in Patients Diagnosed With Ligneous Conjunctivitis
Status: Enrolling
Updated:  7/26/2016
Indiana Hemophilia and Thrombosis Center
mi
from
Indianapolis, IN
Efficacy/Safety of Human Plasminogen Eye Drop in Ligneous Conjunctivitis Patients
A Historically Controlled Phase II/III Study to Evaluate Efficacy and Safety of Kedrion Human Plasminogen Eye Drop Preparation in Patients Diagnosed With Ligneous Conjunctivitis
Status: Enrolling
Updated: 7/26/2016
Indiana Hemophilia and Thrombosis Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Efficacy/Safety of Human Plasminogen Eye Drop in Ligneous Conjunctivitis Patients
A Historically Controlled Phase II/III Study to Evaluate Efficacy and Safety of Kedrion Human Plasminogen Eye Drop Preparation in Patients Diagnosed With Ligneous Conjunctivitis
Status: Enrolling
Updated:  7/26/2016
Meyer Children's Hospital
mi
from
Florence,
Efficacy/Safety of Human Plasminogen Eye Drop in Ligneous Conjunctivitis Patients
A Historically Controlled Phase II/III Study to Evaluate Efficacy and Safety of Kedrion Human Plasminogen Eye Drop Preparation in Patients Diagnosed With Ligneous Conjunctivitis
Status: Enrolling
Updated: 7/26/2016
Meyer Children's Hospital
mi
from
Florence,
Click here to add this to my saved trials
Clinical Evaluation Following Use of SYSTANE® ULTRA in the Management of Dry Eye
Clinical Evaluation Following Use of SYSTANE® ULTRA in the Management of Dry Eye
Status: Enrolling
Updated:  7/26/2016
Contact Alcon Call Center for Trial Locations
mi
from
Fort Worth, TX
Clinical Evaluation Following Use of SYSTANE® ULTRA in the Management of Dry Eye
Clinical Evaluation Following Use of SYSTANE® ULTRA in the Management of Dry Eye
Status: Enrolling
Updated: 7/26/2016
Contact Alcon Call Center for Trial Locations
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Cross-over Comparison of Gabapentin and Memantine as Treatment for Acquired Nystagmus
Investigation and Treatment of Ocular Motor Disorders: Cross-over Comparison of Gabapentin and Memantine as Treatment for Nystagmus
Status: Enrolling
Updated:  7/28/2016
Veterans Affairs Medical Center, 10701 East Boulevard
mi
from
Cleveland, OH
Cross-over Comparison of Gabapentin and Memantine as Treatment for Acquired Nystagmus
Investigation and Treatment of Ocular Motor Disorders: Cross-over Comparison of Gabapentin and Memantine as Treatment for Nystagmus
Status: Enrolling
Updated: 7/28/2016
Veterans Affairs Medical Center, 10701 East Boulevard
mi
from
Cleveland, OH
Click here to add this to my saved trials
NT-501 CNTF Implant for Glaucoma: Safety, Neuroprotection and Neuroenhancement
CNTF Cell Implants For Glaucoma: A Phase I Study
Status: Enrolling
Updated:  8/1/2016
Bascom Palmer Eye Institute, University of Miami
mi
from
Miami, FL
NT-501 CNTF Implant for Glaucoma: Safety, Neuroprotection and Neuroenhancement
CNTF Cell Implants For Glaucoma: A Phase I Study
Status: Enrolling
Updated: 8/1/2016
Bascom Palmer Eye Institute, University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
NT-501 CNTF Implant for Ischemic Optic Neuropathy: Safety, Neuroprotection and Neuroenhancement
Status: Enrolling
Updated:  8/1/2016
Bascom Palmer Eye Institute, University of Miami Miller School of Medicine
mi
from
Miami, FL
NT-501 CNTF Implant for Ischemic Optic Neuropathy: Safety, Neuroprotection and Neuroenhancement
Status: Enrolling
Updated: 8/1/2016
Bascom Palmer Eye Institute, University of Miami Miller School of Medicine
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma
An Adaptive, Multi-center, Randomized, Investigator-masked, Subject-masked, Multiple-dose, Placebo-controlled, Parallel Study to Investigate Efficacy, Safety, Tolerability and Pharmacokinetics of RO5093151 for up to 28 Days in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Morrow, GA
A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma
An Adaptive, Multi-center, Randomized, Investigator-masked, Subject-masked, Multiple-dose, Placebo-controlled, Parallel Study to Investigate Efficacy, Safety, Tolerability and Pharmacokinetics of RO5093151 for up to 28 Days in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Morrow, GA
Click here to add this to my saved trials
A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma
An Adaptive, Multi-center, Randomized, Investigator-masked, Subject-masked, Multiple-dose, Placebo-controlled, Parallel Study to Investigate Efficacy, Safety, Tolerability and Pharmacokinetics of RO5093151 for up to 28 Days in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
High Point, NC
A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma
An Adaptive, Multi-center, Randomized, Investigator-masked, Subject-masked, Multiple-dose, Placebo-controlled, Parallel Study to Investigate Efficacy, Safety, Tolerability and Pharmacokinetics of RO5093151 for up to 28 Days in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
High Point, NC
Click here to add this to my saved trials
A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma
An Adaptive, Multi-center, Randomized, Investigator-masked, Subject-masked, Multiple-dose, Placebo-controlled, Parallel Study to Investigate Efficacy, Safety, Tolerability and Pharmacokinetics of RO5093151 for up to 28 Days in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Mt. Pleasant, SC
A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma
An Adaptive, Multi-center, Randomized, Investigator-masked, Subject-masked, Multiple-dose, Placebo-controlled, Parallel Study to Investigate Efficacy, Safety, Tolerability and Pharmacokinetics of RO5093151 for up to 28 Days in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Mt. Pleasant, SC
Click here to add this to my saved trials
A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma
An Adaptive, Multi-center, Randomized, Investigator-masked, Subject-masked, Multiple-dose, Placebo-controlled, Parallel Study to Investigate Efficacy, Safety, Tolerability and Pharmacokinetics of RO5093151 for up to 28 Days in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated:  8/1/2016
mi
from
Sofia,
A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma
An Adaptive, Multi-center, Randomized, Investigator-masked, Subject-masked, Multiple-dose, Placebo-controlled, Parallel Study to Investigate Efficacy, Safety, Tolerability and Pharmacokinetics of RO5093151 for up to 28 Days in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated: 8/1/2016
mi
from
Sofia,
Click here to add this to my saved trials
A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration
A Multiple-Center, Non-Randomized, Open-Label, Single- and Multiple-Ascending-Dose, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6867461 Following Intravitreal Administration in Patients With Wet Age-Related Macular Degeneration
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Colorado Springs, CO
A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration
A Multiple-Center, Non-Randomized, Open-Label, Single- and Multiple-Ascending-Dose, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6867461 Following Intravitreal Administration in Patients With Wet Age-Related Macular Degeneration
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration
A Multiple-Center, Non-Randomized, Open-Label, Single- and Multiple-Ascending-Dose, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6867461 Following Intravitreal Administration in Patients With Wet Age-Related Macular Degeneration
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Baltimore, MD
A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration
A Multiple-Center, Non-Randomized, Open-Label, Single- and Multiple-Ascending-Dose, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6867461 Following Intravitreal Administration in Patients With Wet Age-Related Macular Degeneration
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration
A Multiple-Center, Non-Randomized, Open-Label, Single- and Multiple-Ascending-Dose, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6867461 Following Intravitreal Administration in Patients With Wet Age-Related Macular Degeneration
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Dallas, TX
A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration
A Multiple-Center, Non-Randomized, Open-Label, Single- and Multiple-Ascending-Dose, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6867461 Following Intravitreal Administration in Patients With Wet Age-Related Macular Degeneration
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration
A Multiple-Center, Non-Randomized, Open-Label, Single- and Multiple-Ascending-Dose, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6867461 Following Intravitreal Administration in Patients With Wet Age-Related Macular Degeneration
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Houston, TX
A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration
A Multiple-Center, Non-Randomized, Open-Label, Single- and Multiple-Ascending-Dose, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6867461 Following Intravitreal Administration in Patients With Wet Age-Related Macular Degeneration
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration
A Multiple-Center, Non-Randomized, Open-Label, Single- and Multiple-Ascending-Dose, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6867461 Following Intravitreal Administration in Patients With Wet Age-Related Macular Degeneration
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Charlottesville, VA
A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration
A Multiple-Center, Non-Randomized, Open-Label, Single- and Multiple-Ascending-Dose, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6867461 Following Intravitreal Administration in Patients With Wet Age-Related Macular Degeneration
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Charlottesville, VA
Click here to add this to my saved trials
A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration
A Multiple-Center, Non-Randomized, Open-Label, Single- and Multiple-Ascending-Dose, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6867461 Following Intravitreal Administration in Patients With Wet Age-Related Macular Degeneration
Status: Enrolling
Updated:  8/1/2016
mi
from
Belfast,
A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration
A Multiple-Center, Non-Randomized, Open-Label, Single- and Multiple-Ascending-Dose, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6867461 Following Intravitreal Administration in Patients With Wet Age-Related Macular Degeneration
Status: Enrolling
Updated: 8/1/2016
mi
from
Belfast,
Click here to add this to my saved trials
Trial Comparing Ketorolac Tromethamine 0.4% & Prednisolone Acetate 1% in Reducing Post-SLT Anterior Chamber Flare & Cells
A Randomized Prospective Double - Masked Controlled Trial Comparing Ketorolac Tromethamine 0.4% and Prednisolone Acetate 1% in Reducing Post-Selective Laser Trabeculoplasty Anterior Chamber Flare and Cells
Status: Enrolling
Updated:  8/8/2016
University of Pittsburgh UPMC Eye Center
mi
from
Pittsburgh, PA
Trial Comparing Ketorolac Tromethamine 0.4% & Prednisolone Acetate 1% in Reducing Post-SLT Anterior Chamber Flare & Cells
A Randomized Prospective Double - Masked Controlled Trial Comparing Ketorolac Tromethamine 0.4% and Prednisolone Acetate 1% in Reducing Post-Selective Laser Trabeculoplasty Anterior Chamber Flare and Cells
Status: Enrolling
Updated: 8/8/2016
University of Pittsburgh UPMC Eye Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Ranibizumab and Bevacizumab for Diabetic Macular Edema
A Phase II Randomized Study to Compare Anti-VEGF Agents in the Treatment of Diabetic Macular Edema (CADME)
Status: Enrolling
Updated:  8/18/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Ranibizumab and Bevacizumab for Diabetic Macular Edema
A Phase II Randomized Study to Compare Anti-VEGF Agents in the Treatment of Diabetic Macular Edema (CADME)
Status: Enrolling
Updated: 8/18/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Ranibizumab and Bevacizumab for Diabetic Macular Edema
A Phase II Randomized Study to Compare Anti-VEGF Agents in the Treatment of Diabetic Macular Edema (CADME)
Status: Enrolling
Updated:  8/18/2016
Bristol Eye Hospital
mi
from
Bristol,
Ranibizumab and Bevacizumab for Diabetic Macular Edema
A Phase II Randomized Study to Compare Anti-VEGF Agents in the Treatment of Diabetic Macular Edema (CADME)
Status: Enrolling
Updated: 8/18/2016
Bristol Eye Hospital
mi
from
Bristol,
Click here to add this to my saved trials
Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study
Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study
Status: Enrolling
Updated:  8/18/2016
Truhlsen Eye Institute, University of Nebraska Medical Center
mi
from
Omaha, NE
Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study
Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study
Status: Enrolling
Updated: 8/18/2016
Truhlsen Eye Institute, University of Nebraska Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST-1)
Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST-1)
Status: Enrolling
Updated:  8/18/2016
Wilmer Eye Institute
mi
from
Baltimore, MD
Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST-1)
Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST-1)
Status: Enrolling
Updated: 8/18/2016
Wilmer Eye Institute
mi
from
Baltimore, MD
Click here to add this to my saved trials
Biomarkers In Retinitis Pigmentosa (BIRP)
Biomarkers In Retinitis Pigmentosa (BIRP)
Status: Enrolling
Updated:  8/18/2016
Wilmer Eye Institute
mi
from
Baltimore, MD
Biomarkers In Retinitis Pigmentosa (BIRP)
Biomarkers In Retinitis Pigmentosa (BIRP)
Status: Enrolling
Updated: 8/18/2016
Wilmer Eye Institute
mi
from
Baltimore, MD
Click here to add this to my saved trials
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  8/25/2016
Sall Research Medical Center, Inc.
mi
from
Artesia, CA
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 8/25/2016
Sall Research Medical Center, Inc.
mi
from
Artesia, CA
Click here to add this to my saved trials
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  8/25/2016
Retina-Vitreous Associates Medical Group
mi
from
Beverly Hills, CA
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 8/25/2016
Retina-Vitreous Associates Medical Group
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  8/25/2016
University of California, Irvine
mi
from
Irvine, CA
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 8/25/2016
University of California, Irvine
mi
from
Irvine, CA
Click here to add this to my saved trials
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  8/25/2016
Loma Linda University Health Care, Dept. of Ophthalmology
mi
from
Loma Linda, CA
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 8/25/2016
Loma Linda University Health Care, Dept. of Ophthalmology
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  8/25/2016
Southern California Desert Retina Consultants, MC
mi
from
Palm Springs, CA
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 8/25/2016
Southern California Desert Retina Consultants, MC
mi
from
Palm Springs, CA
Click here to add this to my saved trials
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  8/25/2016
California Retina Consultants
mi
from
Santa Barbara, CA
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 8/25/2016
California Retina Consultants
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  8/25/2016
Bay Area Retina Associates
mi
from
Walnut Creek, CA
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 8/25/2016
Bay Area Retina Associates
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  8/25/2016
Eldorado Retina Associates
mi
from
Louisville, CO
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 8/25/2016
Eldorado Retina Associates
mi
from
Louisville, CO
Click here to add this to my saved trials
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  8/25/2016
Retina Consultants of Southwest Florida
mi
from
Fort Myers, FL
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 8/25/2016
Retina Consultants of Southwest Florida
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  8/25/2016
Retina Vitreous Consultants
mi
from
Ft. Lauderdale, FL
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 8/25/2016
Retina Vitreous Consultants
mi
from
Ft. Lauderdale, FL
Click here to add this to my saved trials
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  8/25/2016
Central Florida Retina Institute
mi
from
Lakeland, FL
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 8/25/2016
Central Florida Retina Institute
mi
from
Lakeland, FL
Click here to add this to my saved trials
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  8/25/2016
Southeast Retina Center, P.C.
mi
from
Augusta, GA
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 8/25/2016
Southeast Retina Center, P.C.
mi
from
Augusta, GA
Click here to add this to my saved trials
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  8/25/2016
University of Illinois at Chicago Medical Center
mi
from
Chicago, IL
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 8/25/2016
University of Illinois at Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  8/25/2016
Illinois Retina Associates
mi
from
Joliet, IL
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 8/25/2016
Illinois Retina Associates
mi
from
Joliet, IL
Click here to add this to my saved trials
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  8/25/2016
Raj K. Maturi, MD
mi
from
Indianapolis, IN
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 8/25/2016
Raj K. Maturi, MD
mi
from
Indianapolis, IN
Click here to add this to my saved trials